Talampanel
- Generic Name
- Talampanel
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19N3O3
- CAS Number
- 161832-65-1
- Unique Ingredient Identifier
- CVS43XG1L5
- Background
Talampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.
- Indication
For the treatment of epilepsy.
- Associated Conditions
- -
- Associated Therapies
- -
Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 446
- Registration Number
- NCT00982150
A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2010-04-07
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT00964730
- Locations
- 🇺🇸
Cetero Research - Fargo, Fargo, North Dakota, United States
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2011-10-21
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 559
- Registration Number
- NCT00696332
- Locations
- 🇧🇪
Academic Hospital University of Leuven - ALS dept, Leuven, Belgium
🇫🇷C.H.U. de Montpellier - Hopital Gui de Chauliac - Service des Explorations Neurologiques, Montpellier Cedex 5, France
🇨🇦Montreal Neurological Institute, Montreal, Quebec, Canada
Safety and Efficacy of Talampanel in Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00267592
Talampanel to Treat Parkinson's Disease
- Conditions
- First Posted Date
- 2005-04-18
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 40
- Registration Number
- NCT00108667
- Locations
- 🇺🇸
National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States
Talampanel in Treating Patients With Recurrent High-Grade Glioma
- Conditions
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
- Conditions
- Interventions
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00062504
Effect of Talampanel (an AMPA Receptor Blocker) on Brain Activity
- Conditions
- First Posted Date
- 2003-04-02
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 25
- Registration Number
- NCT00057460
- Locations
- 🇺🇸
National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States
Effects of Talampanel on Patients With Advanced Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT00036296
Multicenter Trial for Adults With Partial Seizures
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2011-03-17
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT00034814
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.